Avalon GloboCare Corp.

Change Agents Corporation (formerly Avalon GloboCare Corp.) filed an S-1 registration statement for the resale of up to 35,569,258 shares of common stock by various selling stockholders. The company may receive up to $10 million from the sale of Put Shares under an Equity Purchase Agreement and an additional $9,259.25 if an associated warrant is fully exercised. Recent corporate actions include a name change, the formation of a new subsidiary for drone technology, and securing new debt and equity financing totaling over $1.7 million in principal, though net proceeds were significantly lower after repayments. The company reported an accumulated deficit of $110.4 million as of March 31, 2026, and has only $200,000 in cash as of July 31, 2026, raising substantial doubt about its ability to continue as a going concern.

Change Agents Corporation announced the issuance of 1,550,000 shares of its common stock between July 30 and August 1, 2026. These shares were provided as consideration for services rendered under amendments and addendums to certain outstanding consulting agreements. The company relied on the exemption from registration provided by Section 4(a)(2) of the Securities Act of 1933 for this issuance.

Change Agents Corp. announced the formation of Autonomous Air Defense LLC, a new wholly-owned subsidiary dedicated to AI-enabled autonomous drone surveillance and counter-unmanned aerial systems (C-UAS) technologies. This strategic move marks the company's entry into the defense technology sector, a market projected to reach $20.3 billion by 2030. Major General (Ret.) Malcolm Frost has been appointed to the advisory boards of both Change Agents Corp. and Autonomous Air Defense LLC to guide this initiative.

Change Agents Corporation (formerly Avalon GloboCare Corp.) secured a new $825,000 business loan. The company received net proceeds of $254,350 after repaying a prior $529,400 loan and paying a $41,500 administration fee. The new loan, with a total repayment amount of $1,188,000 including substantial interest, is repayable in 30 weekly installments. Additionally, the company issued 360,000 common shares to the lender in consideration for a forbearance agreement related to the prior loan.

Avalon GloboCare Corp. has entered into an Equity Purchase Agreement with Hudson Global Ventures, LLC, allowing the company to sell up to $10,000,000 of its common stock over a period of up to 36 months. The shares will be purchased at a price of $0.30 per share, with individual purchase requests varying based on the stock's trading price. Additionally, the company issued a warrant for up to 925,925 shares and agreed to a Registration Rights Agreement to facilitate the resale of these securities.

Avalon GloboCare Corp. announced its strategic transformation into an agentic artificial intelligence (AI) software company, rebranding as Change Agents Corp. The company's common stock will begin trading under the new Nasdaq ticker symbol "CHGA" effective July 22, 2026. This move reflects its evolution into a pure-play AI software company, focusing on SaaS applications like Beacon (AI Generative Engine Optimization) and Catch-Up (AI-powered content creation), while also evaluating new opportunities in sectors such as defense and security. The company will continue to distribute its KetoAir™ breathalyzer device.

Avalon GloboCare Corp. filed an S-1 registration statement for a 'best efforts' offering of common stock and warrants, with no minimum proceeds guaranteed. The company reported significant net losses and an accumulated deficit, leading to substantial doubt about its ability to continue as a going concern. Additionally, it received a Nasdaq non-compliance notice for its minimum bid price and has until October 2026 to regain compliance. The company has pivoted its business to AI software and consumer health technology, having recently acquired RPM Interactive and discontinued its THC breathalyzer development.

Avalon GloboCare Corp. entered into a securities purchase agreement to sell 400 shares of Series F Convertible Preferred Stock and 200,000 shares of common stock to an accredited investor for an aggregate purchase price of $400,000. The Series F Preferred Stock is convertible at $0.50 per share and is subject to mandatory redemption at 125% of its stated value. Additionally, the company issued various restricted common shares and stock options to consultants, officers, and non-employee directors for services rendered and as compensation.

Avalon GloboCare Corp. provided an update on its Nevada POOL/PACT Holistic Health Reset program, a four-month wellness initiative supporting 50 first responders. The program, which began in August 2025, utilized Avalon's KetoAir™ breath-based metabolic monitoring technology. The company reported strong participant engagement and adherence, with mid-program data showing individual improvements in metabolic health metrics. An average participant engagement rate of approximately 66% was achieved, and Avalon expects to release additional program data in the near future.

Avalon GloboCare Corp. reported a net loss of $(4.48) million for Q1 2026, a significant increase from $(2.48) million in Q1 2025. The company disclosed a working capital deficit of approximately $(2.77) million and issued a going concern warning due to recurring losses and negative operating cash flow. During the quarter, Avalon GloboCare divested its Avalon RT 9 subsidiary to its chairman and raised $3.25 million through a private placement, contributing to a substantial increase in cash and a decrease in total liabilities.